Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2,430 Mln
P/E Ratio
10.71
P/B Ratio
3.41
Industry P/E
--
Debt to Equity
0.07
ROE
0.39 %
ROCE
35.56 %
Div. Yield
0 %
Book Value
4.4
EPS
1.36
CFO
$-1,294.25 Mln
EBITDA
$-2,046.04 Mln
Net Profit
$-2,024.88 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals (ACAD)
| -19.73 | -15.83 | -15.92 | -13.76 | -14.38 | -20.56 | -9.20 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals (ACAD)
| -41.14 | 96.67 | -31.79 | -56.34 | 24.96 | 164.56 | -46.11 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for... the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130 Read more
President, CEO & Director
Mr. Stephen R. Davis J.D.
President, CEO & Director
Mr. Stephen R. Davis J.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ACADIA Pharmaceuticals Inc (ACAD) stood at $ 1,188 Mln as on 31-Dec-24
The share price of ACADIA Pharmaceuticals Inc (ACAD) is $14.73 (NASDAQ) as of 17-Apr-2025 16:00 EDT. ACADIA Pharmaceuticals Inc (ACAD) has given a return of -14.38% in the last 3 years.
ACADIA Pharmaceuticals Inc (ACAD) has a market capitalisation of $ 2,430 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of ACADIA Pharmaceuticals Inc (ACAD) is 10.71 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ACADIA Pharmaceuticals Inc (ACAD) and enter the required number of quantities and click on buy to purchase the shares of ACADIA Pharmaceuticals Inc (ACAD).
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130
The CEO & director of Mr. Stephen R. Davis J.D.. is ACADIA Pharmaceuticals Inc (ACAD), and CFO & Sr. VP is Mr. Stephen R. Davis J.D..
There is no promoter pledging in ACADIA Pharmaceuticals Inc (ACAD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| ACADIA Pharmaceuticals Inc. (ACAD) | Ratios |
|---|---|
|
Return on equity(%)
|
38.89
|
|
Operating margin(%)
|
8.8
|
|
Net Margin(%)
|
23.64
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ACADIA Pharmaceuticals Inc (ACAD) was $0 Mln.
$0.16
(
